Reviewing Interpace Diagnostics Group (NASDAQ:IDXG) & Nuvectra (NASDAQ:NVTR)

Share on StockTwits

Interpace Diagnostics Group (NASDAQ:IDXG) and Nuvectra (NASDAQ:NVTR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares Interpace Diagnostics Group and Nuvectra’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $21.90 million 1.33 -$12.19 million ($0.43) -1.77
Nuvectra $48.83 million 0.60 -$48.13 million ($3.19) -0.51

Interpace Diagnostics Group has higher earnings, but lower revenue than Nuvectra. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Nuvectra, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

22.8% of Interpace Diagnostics Group shares are held by institutional investors. Comparatively, 73.8% of Nuvectra shares are held by institutional investors. 2.8% of Interpace Diagnostics Group shares are held by company insiders. Comparatively, 2.9% of Nuvectra shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Interpace Diagnostics Group has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Nuvectra has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Profitability

This table compares Interpace Diagnostics Group and Nuvectra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -65.86% -42.91% -28.66%
Nuvectra -99.08% -58.23% -34.01%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Interpace Diagnostics Group and Nuvectra, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 3 0 3.00
Nuvectra 0 0 3 0 3.00

Interpace Diagnostics Group presently has a consensus target price of $3.33, suggesting a potential upside of 338.60%. Nuvectra has a consensus target price of $10.67, suggesting a potential upside of 550.41%. Given Nuvectra’s higher probable upside, analysts clearly believe Nuvectra is more favorable than Interpace Diagnostics Group.

Summary

Interpace Diagnostics Group beats Nuvectra on 7 of the 12 factors compared between the two stocks.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.